At a Glance
- Companies: AbbVie & Gilead Sciences
- Locations: North Chicago, Illinois (AbbVie); Foster City, California (Gilead)
- Headline figures: AbbVie: up to roughly $1.2 billion for DLL3 T‑cell engager rights; Gilead: multi‑component deal around a Polθ inhibitor with undisclosed total milestones
- Focus area: Clinical‑stage oncology: DLL3‑targeted T‑cell engager; DNA damage response (Polθ) inhibitor
- Next steps: Advance assets through early clinical development and integrate into broader solid tumour portfolios
What happened?
On the business development side, AbbVie and Gilead each unveiled new oncology deals disclosed around 2 January 2026, effectively “gifting themselves” fresh clinical‑stage cancer programs to start the year. The transactions centre on in‑licensing and option structures for promising solid tumour assets, highlighting a continued appetite for external innovation in cancer despite a selective dealmaking environment.
Why does it matter?
The AbbVie and Gilead moves show that large biopharma groups remain prepared to commit significant capital to de‑risked yet still early oncology mechanisms, particularly those with biomarker‑guided strategies and first‑ or best‑in‑class potential. These deals also illustrate how 2026 BD is likely to skew: targeted, mechanism‑rich transactions in oncology rather than broad platform bets, aligning spend with clearly defined value inflection points.
Who’s behind it?
AbbVie continues to rebuild and diversify its oncology pipeline around T‑cell engagers, antibody‑drug conjugates and other targeted biologics, adding new assets to complement earlier acquisitions such as ImmunoGen. Gilead, meanwhile, is extending its oncology strategy beyond Trodelvy and its existing cell therapy portfolio by layering in additional precision‑oncology and DNA damage response approaches through partnerships.
How was it achieved?
AbbVie’s agreement is structured with an upfront payment, option fees and downstream milestones tied to development and commercial success, with ex‑China or regional rights a key component of the economics. Gilead’s deal deploys a smaller upfront outlay plus technology‑transfer payments and typical biobucks, reflecting an early‑stage asset where value is concentrated in future proof‑of‑concept readouts.
What’s next?
Both companies are expected to move quickly into, or through, phase 1 studies, using emerging biomarker and safety data to shape go/no‑go decisions and potential expansion into combination regimens. With JPMorgan 2026 approaching, these transactions are likely early signals of a broader oncology BD cycle, as big pharma looks to secure pipeline depth ahead of looming patent cliffs and competitive launches.